Apartment Investment and Management Co vs ResMed Inc. — how do they compare? Apartment Investment and Management Co trades at $2.61 (market cap $376.16M), while ResMed Inc. trades at $224.67 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 86.7× Apartment Investment and Management Co's market cap, and ResMed Inc. pays a 1.17% dividend while Apartment Investment and Management Co pays none. Which is the better fit depends on your goals.
| AIV | RMD | |
|---|---|---|
Market Cap | $376.16M | $32.61B |
Sector | Real Estate | Health |
52-Week High | $7.93 | $293.73 |
52-Week Low | $2.59 | $182.82 |
Enterprise Value | $738.32M | $31.97B |
Dividend Yield | — | 1.17% |
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.62, down 1.5% recently, with a bearish technical signal from moving averages. The company reported Q4 2025 EPS of $1.06, beating expectations, but revenue declined to $138.49M in 2025. Valuation ratios show a low P/B of 0.76, suggesting potential undervaluation, while a net income margin of 400.05% reflects significant one-time tax benefits. Cash flow improved with a net inflow of $234M in 2025.
Outlook is mixed: strong profitability metrics and a scheduled dividend in 2026 offer upside, but inconsistent earnings history and revenue volatility pose risks. Analyst consensus is cautious with 33% buy ratings. Investors should weigh the attractive valuation against operational challenges in the real estate sector.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Trailing returns across standard periods
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →